Noticias y Actividades de Evaxion Biotech

Evaxion Biotech es una empresa que cotiza bajo el símbolo de cotización EVAX (DK).

Ver el organigrama con sus 14 ejecutivos principales

Biografías más buscadas en Evaxion Biotech

• Helen Tayton-Martin, Chief Executive Officer
• Roberto Prego Pineda, Board Member
• Marianne Søgaard, Chairman of the Board

Recientes movimientos de ejecutivos en Evaxion Biotech

• Birgitte Rønø que ha sido Chief Scientific Officer, ha ascendido a Chief Science and Chief Operating Officer  (noticia publicada el 27 de abril de 2026).
• Helen Tayton-Martin que es Director, ascenderá Chief Executive Officer el 24 de nov.. de 2025  (noticia publicada el 28 de octubre de 2025).
• Birgitte Rønø que ha sido Interim Chief Executive Officer and Chief Scientific Officer, pasa a ser Chief Scientific Officer  (noticia publicada el 27 de octubre de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Evaxion Biotech.

Evaxion Biotech tiene 2.428 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).

Popular M&A news in Biotecnología

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado el 17 de julio de 2026).
• GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado el 15 de julio de 2026).

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Patrick Enright - Director en CuraSen Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Evaxion Biotech

• Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials | Evaxion Biotech
• Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform | Evaxion Biotech
• Evaxion significantly expands vaccine development collaboration with MSD | Evaxion Biotech
• Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction | Evaxion Biotech
• Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 | Evaxion Biotech
• Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 | Evaxion Biotech
• Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 | Evaxion Biotech
• Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September | Evaxion Biotech
• Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14 | Evaxion Biotech
• Evaxion Announces Business Update and Second Quarter 2024 Financial Results | Evaxion Biotech
• View more press releases Close

Redes sociales sobre Evaxion Biotech

• Evaxion Biotech en Wikipedia, Google News y Yahoo Finance
• Evaxion Biotech en LinkedIn, Twitter y YouTube